Latest news
How the Challenges of Glioblastoma Treatment Highlight New Opportunities for Next-Generation Antibody Therapeutics - BioPharm InternationalBioPharm International · Fri, 07 Aug 2026 19:52:06 GMTKaigene Enters into Exclusive Licensing Agreement with Taisho Pharmaceutical for Next-Generation Autoimmune Asset KG006 in Japan - PR NewswirePR Newswire · Thu, 30 Jul 2026 07:00:00 GMT